Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer

Recruiting

Phase 1

MYTX-011Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer

Sponsor:

Mythic Therapeutics

Code:

NCT05652868

Conditions

NSCLC

NSCLC Stage IV

NSCLC Stage IIIB

Non-Small Cell Lung Cancer

Advanced Non-Small Cell Squamous Lung Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

MYTX-011

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-03. This information was provided to ClinicalTrials.gov by Mythic Therapeutics on 2025-06-29.